Patients with stable coronary artery disease
Conditions
Interventions
Colchicine at 0.5mg per day for 1 week
Placebo
Sponsors
University of the Ryukyus
Tokyo Medical University, HIroshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with coronary artery disease with condition being stable for previous 6 months. 2) Aged 20 years and over and less than 70 years old 3) Patients who voluntarily give informed consent after full explanation of the study Coronary artery disease is defined as 1)significant stenosis (>AHA 75% ) of coronary arteries by CAG or coronary artery CT 2) history of PCI or CABG 3) history of acute coronary syndrome
Exclusion criteria
Exclusion criteria: 1) Patients aged 70 and over and less than 20 years old 2) Patients receiving drugs interacting with colchicine through CYP3A4 and p-glycoprotein listed in the label. 3) Patients with impaired renal function being eGFR less than 30ml/min/1.73m2 4) Patients with liver cirrhosis 5) Patients with cholestasis 6) Patients with active malignant tumor 7) Patients who are expected mothers or on breast feeding. 8) Inappropriate patients for this study judged by doctors in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endothelial function measured by FMD. | — |
Countries
Japan
Contacts
Public ContactShinichiro Ueda
University of the Ryukyus Department of Clinical Pharmacology & Therapeutics
Outcome results
None listed